Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma — Stella

Home/Multiple Myeloma/BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Multiple Myeloma trials

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

Key details

Phase

Safety & dosing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~80 participants

Started

February 2025

Primary completion

December 2026

Age range

18 Years – 70 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.